[overlays src=”img src=”” in=”fadeIn” out=”fadeOut” width=”100″ height=”100″ color=”#969696″ opacity=”0.36″ text_position=”overlay_bottom_left” animation_speed=”9″ ]UCI’s Dr. Henry Klassen helped create the stem-cell based therapy used in the current jCyte clinical trial.[/overlays]

A new cure for Retinitis Pigmentosa

With support from cell therapy company jCyte, and the California Institute for Regenerative Medicine, Dr. Baruch Kupperman, professor of ophthalmology and biomedical engineering at UCI, is leading a phase 2b trial for the jCyte’s developmental Retinitis Pigmentosa (RP) therapy, jCell. The trial will be held at two sites, and Kupperman will oversee the clinical research effort at the on-campus Gavin Herbert Eye Institute. The trial’s primary goal is to assess changes in visual function following jCell treatment, focusing on visual acuity, visual fields, contrast sensitivity and the ability to navigate a mobility course. RP is an incurable genetic condition that destroys retinal cells and usually strikes people in their teens. Many patients are legally blind by the time they reach 40. Founded by UCI researchers Dr. Henry Klassen, and Dr. Jing Yang, jCyte was spun out from research conducted at the UCI School of Medicine and has been working to advance its RP therapy since 2012. The company has also received an $8.3 million grant from the California Institute for Regenerative Medicine to help fund the trial.